Skip to Content

Nelarabine Pregnancy and Breastfeeding Warnings

Nelarabine is also known as: Arranon

Medically reviewed on August 4, 2017.

Nelarabine Pregnancy Warnings

Nelarabine has been assigned to pregnancy category D by the FDA. Animal studies have revealed evidence of increased incidences of fetal malformations, anomalies, and variations which included cleft palate, absent pollices (digits), absent gall bladder, absent accessory lung lobes, fused or extra sternebrae and delayed ossification, maternal body weight gain, and reduced fetal body weights. There are no controlled data in human pregnancy. Nelarabine should only be given during pregnancy when there are no alternatives and benefit outweighs risk. Women of child-bearing potential should be advised to avoid becoming pregnant while receiving treatment with nelarabine.

Nelarabine may cause fetal harm when administered to a pregnant woman. If nelarabine is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with nelarabine.

See references

Nelarabine Breastfeeding Warnings

There are no data on the excretion of nelarabine or ara-G into human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from nelarabine, nursing should be discontinued in women who are receiving therapy with nelarabine.

See references

References for pregnancy information

  1. "Product Information. Arranon (nelarabine)." GlaxoSmithKline, Research Triangle Park, NC.

References for breastfeeding information

  1. "Product Information. Arranon (nelarabine)." GlaxoSmithKline, Research Triangle Park, NC.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide